|1.||Peters, Wilbert H M: 3 articles (01/2014 - 01/2009)|
|2.||Carty, E: 3 articles (05/2002 - 06/2000)|
|3.||Rampton, D S: 3 articles (05/2002 - 06/2000)|
|4.||Cummins, Robert: 2 articles (05/2014 - 01/2011)|
|5.||Pidgeon, Graham P: 2 articles (05/2014 - 01/2011)|
|6.||O'Byrne, Kenneth J: 2 articles (05/2014 - 01/2011)|
|7.||Gately, Kathy: 2 articles (05/2014 - 01/2011)|
|8.||Nagengast, Fokko M: 2 articles (01/2014 - 01/2009)|
|9.||Roelofs, Hennie M J: 2 articles (01/2014 - 01/2009)|
|10.||Te Morsche, Rene H M: 2 articles (01/2014 - 07/2009)|
09/01/2004 - "Platelets are essential not only for clotting, but have an emerging role in inflammation in part due to their release or production of the proinflammatory and proatherogenic mediators CD40 ligand (CD40L) and thromboxanes (TXs). "
07/01/2001 - "Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes."
08/01/1989 - "Vasoactive mediators, such as prostaglandins and thromboxanes, are released after endotoxin and are involved in inflammation. "
12/01/1977 - "Prostaglandins, thromboxanes, and polymorphonuclear leukocytes: mediation and modulation of inflammation."
11/01/1979 - "They induce the classical signs of inflammation such asvescular dilatation, increase in permeability, pain, hyperalgesia etc. By the same process, the thromboxanes and prostacycline are generated which mainly act on the coagulation system. "
|2.||Cardiovascular Diseases (Cardiovascular Disease)
01/01/1985 - "Thromboxanes as mediators of cardiovascular disease states."
04/01/2008 - "Polyunsaturated fatty acids are also precursors of ''hormonal'' molecules, often with opposing effects, prostaglandins, prostacyclins, thromboxanes, leukotrienes, lipossines, resolvines, protectines that regulate immunity, platelet aggregation, inflammation, etc. They showed that raised levels of polyunsaturated fatty acids omega-3 in tissue correlate with a reduced incidence of degenerative cardiovascular disease, some mental illnesses such as depression, and neuro-degenerative diseases such as Alzheimer's. "
03/01/2012 - "Since then, researchers have shown a growing interest in polyunsaturated fatty acids (PUFA) as precursors of "lipid mediator" molecules, often with opposing effects, prostaglandins, prostacyclins, thromboxanes, leukotrienes, lipossines, resolvines, protectines, maresins that regulate immunity, platelet aggregation, inflammation, etc. They showed that the balance between omega-3 and omega-6 acids has a profound influence on all the body's inflammatory responses and a raised level of PUFA omega-3 in tissue correlate with a reduced incidence of degenerative cardiovascular disease, some mental illnesses such as depression, and neuro-degenerative diseases such as Alzheimer's. "
05/01/1997 - "Lack of efficacy of OKY-046 in isolated studies suggests the involvement of platelet-derived thromboxanes in the reperfusion injury as these are not available in isolated heart preparations."
05/01/1997 - "The present study demonstrates a definite involvement of leukotrienes and thromboxanes in reperfusion injury. "
|4.||Myocardial Ischemia (Ischemic Heart Diseases)
04/01/1989 - "Inhibition of the enzyme that synthesizes thromboxanes may protect against the development of ventricular fibrillation (VF) during acute myocardial ischemia. "
11/01/1982 - "The efficacy of aspirin, a cyclooxygenase inhibitor, further suggests that the products of arachidonate metabolism (e.g., thromboxanes) have a fundamental role in the genesis of platelet-mediated myocardial ischemia."
08/01/1982 - "Furthermore, the fact that cardiac perfusion was preserved during a thrombin challenge of platelets from aspirin-treated donors establishes a fundamental role for the products of cyclooxygenase activity (e.g., thromboxanes) in the genesis of this form of myocardial ischemia."
01/01/1981 - "Recently in some cases of myocardial infarction, coronary artery spasm has been demonstrated angiographically; thromboxanes, vasoconstrictive and platelet aggregating substances, are released by platelets; thromboxanes, vasoconstrictive and platelet aggregating substances, are released by platelets during myocardial ischemia as an increase of prostaglandin synthesis, like prostacyclin, is stimulated by ischemia and hypoxia. "
|5.||Asthma (Bronchial Asthma)
01/01/1986 - "The effect was more marked in non-infected wheezy bronchitis (83.55% response) than in bronchial asthma (56.5% response), perhaps because factors such as leukotrienes, prostaglandins and thromboxanes tend to produce a sustained bronchoconstriction in the latter condition. "
03/01/1987 - "The lack of therapeutic efficacy of antihistaminic drugs in the treatment of asthma has led to the search and discovery of other bronchoconstrictor agents, particularly leukotrienes, thromboxanes, and platelet-activating factor. "
09/01/1997 - "The proposed mechanism of effect states that mono(2-ethylhexyl) phthalate (MEHP), the primary hydrolysis product of DEHP, mimics the inducing prostaglandins (PG) PGD(2), 9alpha,11betaPGF2, and PGF2alpha, and thromboxanes in the lungs, thereby increasing the risk of inducing inflammation in the airways, which is a characteristic of asthma."
|4.||Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)
|6.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|7.||Aspirin (Acetylsalicylic Acid)
|8.||Platelet Activating Factor
|2.||Transplantation (Transplant Recipients)